📣 Introducing Tracenable Pro: Unlock Unlimited Data Exports & Disclosures Access.
In 2023, Dermapharm Holding conducted an environmental assessment and disclosed corporate waste management data in accordance with recognized sustainability reporting standards.The company provided a breakdown of its waste by type (hazardous vs non-hazardous) and treatment method (recovery vs disposal), enabling greater transparency into its waste handling and environmental practices.
| Metric (tonnes) | 2023 | 2022 | 2021 | 2020 - 2017 |
|---|---|---|---|---|
Total Waste Generated | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Waste Recovered | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Hazardous Waste Generated | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Non-Hazardous Waste Disposed | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Dermapharm Holding’s data sources below and access millions more through our Disclosure Search.
In 2023, Dermapharm Holding generated a total of 8,033 metric tonnes of waste.a
Of this amount, 2.55% of Dermapharm Holding's total waste generated of was classified as hazardous waste, characterized by properties such as toxicity, flammability, corrosiveness, or reactivity that may pose risks to human health, ecosystems, or the environment.97.46% was identified as non-hazardous waste, generally considered less harmful and subject to lighter regulatory controls.a
Since 2019, Dermapharm Holding's total waste generation fell by 2.3%, but rose by 57.94% in 2023, potentially reflecting a temporary surge in activity or inconsistency in waste control strategies.a
Over the same period, Dermapharm Holding saw a long-term increase of 41.77% in hazardous waste share, but a 9.24% reduction in 2023, indicating a recent improvement that may reflect updated production inputs, enhanced treatment, or stricter controls.a
Overall, Dermapharm Holding's waste and hazardousness trends are mixed or inconclusive. A more detailed review of its materials, industry standards, and operational changes would help clarify the net environmental impact of its waste strategy.a